Triptans News and Research

RSS

MAP Pharmaceuticals announces net loss of $13.4M for fourth-quarter 2009

MAP Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Aradigm Corporation announced today that it received the $4 million milestone payment from Zogenix, Inc. (“Zogenix”) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free delivery system. The Company will receive quarterly royalty payments on all SUMAVEL DosePro sales. In 2006, the Company sold all assets related to the Intraject* needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.

5 Feb 2010

Sumavel DosePro and Levadex to earn up to $400M by 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals' needle-free Sumavel DosePro, which launched earlier this month in the United States, and MAP Pharmaceuticals' orally-inhaled Levadex will earn approximately $400 million in combined sales by 2018 in the migraine drug market.

27 Jan 2010

Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented

MAP Pharmaceuticals, Inc. announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX orally inhaled migraine therapy, currently in development, at the 14th Congress of the International Headache Society.

11 Sep 2009

Investigational, orally-inhaled therapy effective in treating migraines

A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines.

12 Aug 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

FDA approves tapentadol immediate-release tablets for pain in adults

Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.

21 Nov 2008

Medications containing barbiturates or narcotics may make migraine worse

A team of researchers led by investigators at the Albert Einstein College of Medicine of Yeshiva University has determined that certain commonly-prescribed medications may have the unintended consequence of increasing the frequency of migraine attacks.

18 Nov 2008

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches.

7 Sep 2008

Hope on the horizon for migraine sufferers

A generation of anti-migraine drugs with fewer side effects than existing treatments could be available to sufferers within three years.

11 Jun 2008

Migraine sufferers may have form of brain damage

Scientists in the U.S. are suggesting that people with migraines may also be suffering from some form of brain damage.

2 May 2007

Combination of sumatriptan and naproxen sodium for migraine more effective than single medications

Combining two different types of treatment for migraine results in better symptom relief than taking either one of the medications, according to a study in the April 4 issue of JAMA .

4 Apr 2007

Multimechanism-targeted therapy for migraine more effective than single medications

Combining two different types of treatment for migraine results in better symptom relief than taking either one of the medications, according to a study in the April 4 issue of JAMA.

3 Apr 2007

Zolmitriptan nasal spray may be safe and effective in treating painful cluster headaches

Zolmitriptan nasal spray, used to treat migraine headaches, also may be safe and effective in treating painful cluster headaches, according to an article posted online today that will appear in the November 2006 print issue of Archives of Neurology.

12 Sep 2006

High narcotic use among headache sufferers

A new analysis of nearly 6.2 million insured patients shows that migraine was under diagnosed and often untreated.

9 Mar 2006

Adult nasal spray helps teenagers cope with migraines

A Florida researcher reports that a prescription nasal spray approved for adults with migraines also helps teenagers and potentially offers relief for a population which is underserved in this respect.

26 Jun 2005

Kids as young as 6 who get frequent headaches may be using over-the-counter pain relievers too much

Kids as young as 6 who get frequent headaches may be using over-the-counter pain relievers far more than they should, and often without their parents' knowledge, suggests a study being presented at the 46th Annual Scientific Meeting of the American Headache Society (AHS).

11 Jun 2004